secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001711279-22-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech reports FY2021 net loss $69.6M, cash $502.5M; on track for Vyjuvek BLA in 1H 2022
--------------------------------------------------------------------------------

- Net loss Q4 2021 $21.8M ($0.94/share); full year $69.6M ($3.13/share) vs. $32.2M ($1.71) in 2020.
- Cash & equivalents $502.5M at Dec 31, 2021, up from $271.3M; net proceeds from public offerings.
- Positive Phase 3 GEM-3 data for Vyjuvek (DEB); BLA filing expected 1H 2022, MAA in 2H 2022.
- Phase 1 trial of KB407 for cystic fibrosis expected to start in Australia 1H 2022; US trial in 2H 2022.
- Suma Krishnan promoted to President R&D effective Feb 25, 2022; she was COO and founder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127922000007/0001711279-22-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127922000007/krys-20220225.htm
  HTML page:      https://secwatch.observer/filing/0001711279-22-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer